⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYNB News
Kyntra Bio, Inc. Common Stock
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
globenewswire.com
KYNB
FGEN
Kyntra Bio to Participate in Upcoming Investor Conferences
globenewswire.com
KYNB
FGEN